Knee replacements: The new fad?

Bad knees are a common conversation starter when climbing the stairs alongside a middle-aged stranger. But in reality, people seem to be jumping the gun on dealing with the issue. Increasing numbers of knee replacements are startling, and the surgery doesn’t necessarily yield positive results. The New York Times reports: There’s no doubt that knee replacements […]


Shire confirms in talks with AbbVie on takeover bid

(Reuters) – Shire Plc on Friday confirmed it has held a meeting with U.S. drugmaker AbbVie Inc to discuss AbbVie’s takeover bid for the Dublin-based maker of drugs for rare diseases. Shire, in a release, did not provide any additional information about the meeting, saying it would provide a further update “when appropriate.” It added […]

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

Devices & Diagnostics

Shock absorbers for the human body? Implant could help active patients avoid total knee replacements longer

Think shock absorbers for the human body. Moximed could help active and young patients who have osteoarthritis prolong the amount of time before total knee replacement. The Heyward, Calif.-based company’s Kinespring Knee Implant System is a medical device that absorbs part of the load put on the knee, without changing anatomy. The device is positioned […]


CHTP’s arthritis drug fails phase 2; now everything rides on Northera

Chelsea Therapeutics‘ (NASDAQ:CHTP) rheumatoid arthritis treatment failed in phase 2 clinical trials and leaves the beleaguered drug developer to focus its remaining resources on an orphan drug candidate that has already fallen short of regulatory approval. The experimental rheumatoid arthritis drug CH-4051 demonstrated some effect on patients, but did not prove better than existing rheumatoid […]


How arthritis drug Vimovo shaped POZN’s strategy on its heart drug

Arthritis represents a large medical need but it is served by several products that carry gastrointestinal risks. Arthritis treatment Vimovo, developed as an alternative that’s easier on the stomach, was intended to address that need. Backed by the marketing muscle of pharma giant AstraZeneca (NYSE:AZN), Pozen (NASDAQ:POZN), which developed the drug, had every expectation it […]


GSK grips arthritis compounds from drug partner Galapagos

GlaxoSmithKline (NYSE:GSK) is strengthening its prospects of developing a new arthritis treatment by licensing two anti-inflammatory compounds from drug partner Galapagos NV (OTC:GLPYY). Belgium-based Galapagos said GSK has exercised its option on compounds GLPG0778 and GLPG0555, both of which were developed within the partnership. Galapagos now stands to receive from GSK an option fee payment […]


Cardinal Health launches infusion therapy tool for rheumatology practices

Pharmaceuticals distributor Cardinal Health (NYSE:CAH) has launched a web-based tool to help rheumatology practices better manage infusion therapy patients. Cardinal’s new InfusaTrack software is designed to make it easier for community rheumatology practices to offer in-office infusion therapy, which involves administering medication through a needle or catheter for patients whose conditions are too severe to […]


GSK licenses ChemoCentryx arthritis treatment to bolster drug pipeline

GlaxoSmithKline (NYSE:GSK) is strengthening its drug pipeline with an experimental arthritis treatment from drug partner ChemoCentryx. The pharmaceutical giant has exercised an option for an exclusive license to develop ChemoCentryx’s investigational drug CCX354, which recently produced positive phase 2 clinical trial results in a study of patients with rheumatoid arthritis. Under terms of the collaboration […]

MedCity Influencers

De-Stressing the Holidays and Enjoying the Season More

We’re in the thick of it now. The thick of the holidays, that is. The season offers wonderful opportunities to connect with family and friends combined with a plethora of ways to amplify stress. For people with arthritis, or any chronic disease, stress can make their pain worse. And fatigue, which often goes hand-in-hand with […]